{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:31:20Z","timestamp":1785699080984,"version":"3.56.0"},"reference-count":55,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Although the primary elimination pathway for most tyrosine kinase inhibitors (TKI) involves CYP3A4-mediated metabolism, the mechanism by which these agents are brought into hepatocytes remains unclear. In this study, we optimized and validated a competitive counterflow (CCF) assay to examine TKIs as substrates of the hepatic uptake transporter OATP1B1. The CCF method was based on the stimulated efflux of radiolabeled estradiol-17\u03b2-glucuronide under steady-state conditions in HEK293 cells engineered to overexpress OATP1B1. Of the 62 approved TKIs examined, 13 agents were identified as putative substrates of OATP1B1, and pazopanib was selected as a representative hit for further validation studies. The transport of pazopanib by OATP1B1 was confirmed by decreased activity of its target VEGFR2 in OATP1B1-overexpressing cells, but not cells lacking OATP1B1, consistent with molecular docking analyses indicating an overlapping binding orientation on OATP1B1 with the known substrate estrone-3-sulfate. In addition, the liver-to-plasma ratio of pazopanib in vivo was decreased in mice with a deficiency of the orthologous transporters, and this was accompanied by diminished pazopanib-induced hepatotoxicity, as determined by changes in the levels of liver transaminases. Our study supports the utility of CCF assays to assess substrate affinity for OATP1B1 within a large set of agents in the class of TKIs and sheds light on the mechanism by which these agents are taken up into hepatocytes in advance of metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Despite the established exposure\u2013pharmacodynamic relationships for many TKIs, the mechanisms underlying the agents\u2019 unpredictable pharmacokinetic profiles remain poorly understood. We report here that the disposition of many TKIs depends on hepatic transport by OATP1B1, a process that has toxicologic ramifications for agents that are associated with hepatotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0332","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T09:30:33Z","timestamp":1724923833000},"page":"2489-2497","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1361-8654","authenticated-orcid":false,"given":"Thomas","family":"Drabison","sequence":"first","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-7408","authenticated-orcid":false,"given":"Mike","family":"Boeckman","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-5785","authenticated-orcid":false,"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-3295","authenticated-orcid":false,"given":"Kevin M.","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-5756","authenticated-orcid":false,"given":"Peter","family":"de Bruijn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-2699","authenticated-orcid":false,"given":"Mahesh R.","family":"Nepal","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4505-3670","authenticated-orcid":false,"given":"Josie A.","family":"Silvaroli","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6478-6907","authenticated-orcid":false,"given":"Anika T.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-675X","authenticated-orcid":false,"given":"Eric D.","family":"Eisenmann","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7396-3225","authenticated-orcid":false,"given":"Xiaolin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9408-0539","authenticated-orcid":false,"given":"Navjotsingh","family":"Pabla","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3062-3252","authenticated-orcid":false,"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9806-7734","authenticated-orcid":false,"given":"Shuiying","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-6644","authenticated-orcid":false,"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-5160","authenticated-orcid":false,"given":"Zahra","family":"Talebi","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"2025040317231902100_bib1","first-page":"35","article-title":"From the food and drug administration","volume":"286","author":"Schwetz","year":"2001","journal-title":"JAMA"},{"key":"2025040317231902100_bib2","doi-asserted-by":"crossref","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"2025040317231902100_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"2025040317231902100_bib4","first-page":"923","article-title":"The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection","volume":"9","author":"Jin","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl 1","key":"2025040317231902100_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bcpt.13623","article-title":"Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions","volume":"130","author":"Eisenmann","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025040317231902100_bib6","doi-asserted-by":"crossref","first-page":"80083","DOI":"10.18632\/oncotarget.11657","article-title":"Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome","volume":"7","author":"Iurlo","year":"2016","journal-title":"Oncotarget"},{"key":"2025040317231902100_bib7","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"2025040317231902100_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J Clin Oncol"},{"key":"2025040317231902100_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025040317231902100_bib10","doi-asserted-by":"crossref","first-page":"108256","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharmacol Ther"},{"key":"2025040317231902100_bib11","doi-asserted-by":"crossref","first-page":"e2020168118","DOI":"10.1073\/pnas.2020168118","article-title":"Targeting OCT3 attenuates doxorubicin-induced cardiac injury","volume":"118","author":"Huang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317231902100_bib12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1172\/JCI96160","article-title":"OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity","volume":"128","author":"Leblanc","year":"2018","journal-title":"J Clin Invest"},{"key":"2025040317231902100_bib13","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025040317231902100_bib14","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.3390\/molecules27206815","article-title":"Itraconazole-induced increases in gilteritinib exposure are mediated by CYP3A and OATP1B","volume":"27","author":"Garrison","year":"2022","journal-title":"Molecules"},{"key":"2025040317231902100_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jpba.2018.11.030","article-title":"Development of a validated LC-MS\/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients","volume":"164","author":"Chatziathanasiadou","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"2025040317231902100_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ijc.34922","article-title":"Darolutamide does not interfere with OATP-mediated uptake of docetaxel","volume":"155","author":"Buck","year":"2024","journal-title":"Int J Cancer"},{"key":"2025040317231902100_bib17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/pharmaceutics14040694","article-title":"Interaction of antifungal drugs with CYP3A- and OATP1B-mediated venetoclax elimination","volume":"14","author":"Eisenmann","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025040317231902100_bib18","doi-asserted-by":"crossref","first-page":"969363","DOI":"10.3389\/fphys.2022.969363","article-title":"Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3","volume":"13","author":"Schnegelberger","year":"2022","journal-title":"Front Physiol"},{"key":"2025040317231902100_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12885-019-6472-9","article-title":"Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers","volume":"20","author":"Fowler","year":"2020","journal-title":"BMC Cancer"},{"key":"2025040317231902100_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/1078155216682311","article-title":"Drug-drug interactions in patients receiving tyrosine kinase inhibitors","volume":"24","author":"Keller","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"2025040317231902100_bib21","first-page":"1719","article-title":"Drug-drug interactions in patients using tyrosine kinase inhibitors: a multicenter retrospective study","volume":"24","author":"Ergun","year":"2019","journal-title":"J BUON"},{"key":"2025040317231902100_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.23","article-title":"Drug-induced liver injury: the role of drug metabolism and transport","volume":"53","author":"Corsini","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2025040317231902100_bib23","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1073\/pnas.1424313112","article-title":"Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4\/6 and OCT2 functions","volume":"112","author":"Pabla","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317231902100_bib24","doi-asserted-by":"crossref","first-page":"10880","DOI":"10.1038\/ncomms10880","article-title":"A phosphotyrosine switch regulates organic cation transporters","volume":"7","author":"Sprowl","year":"2016","journal-title":"Nat Commun"},{"key":"2025040317231902100_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"key":"2025040317231902100_bib26","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41467-020-15638-6","article-title":"A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"2025040317231902100_bib27","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/s41467-023-41552-8","article-title":"Structure of human drug transporters OATP1B1 and OATP1B3","volume":"14","author":"Ciut\u0103","year":"2023","journal-title":"Nat Commun"},{"key":"2025040317231902100_bib28","doi-asserted-by":"crossref","first-page":"e3056","DOI":"10.21769\/BioProtoc.3056","article-title":"Murine pharmacokinetic studies","volume":"8","author":"Leblanc","year":"2018","journal-title":"Bio Protoc"},{"key":"2025040317231902100_bib29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/00498254.2018.1489167","article-title":"A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice","volume":"49","author":"Wang","year":"2019","journal-title":"Xenobiotica"},{"key":"2025040317231902100_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4155\/bio.15.235","article-title":"Development and clinical validation of an LC-MS\/MS method for the quantification of pazopanib in DBS","volume":"8","author":"Verheijen","year":"2016","journal-title":"Bioanalysis"},{"key":"2025040317231902100_bib31","doi-asserted-by":"crossref","first-page":"F56","DOI":"10.1152\/ajprenal.00486.2012","article-title":"Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2","volume":"304","author":"Harper","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025040317231902100_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-023-04615-7","article-title":"Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients","volume":"93","author":"Westerdijk","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025040317231902100_bib33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-016-3112-9","article-title":"Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network","volume":"78","author":"Shantakumar","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025040317231902100_bib34","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","article-title":"Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients","volume":"51","author":"Powles","year":"2015","journal-title":"Eur J Cancer"},{"key":"2025040317231902100_bib35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3390\/metabo12090852","article-title":"Biological role of pazopanib and sunitinib aldehyde derivatives in drug-induced liver injury","volume":"12","author":"Maillard","year":"2022","journal-title":"Metabolites"},{"key":"2025040317231902100_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3073","article-title":"Pazopanib","volume":"9","author":"Bukowski","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2025040317231902100_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.09069","article-title":"Competitive counterflow (CCF) to distinguish between transported and non-transported inhibitors of MATE1 and MATE2-K","volume":"34","author":"Martinez-Guerrero","year":"2020","journal-title":"FASEB J"},{"key":"2025040317231902100_bib38","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.molpharmaceut.8b00631","article-title":"Establishment and validation of competitive counterflow as a method to detect substrates of the organic anion transporting polypeptide 2B1","volume":"15","author":"Sch\u00e4fer","year":"2018","journal-title":"Mol Pharm"},{"key":"2025040317231902100_bib39","doi-asserted-by":"crossref","first-page":"e23223","DOI":"10.1096\/fj.202300530RR","article-title":"The fluorescence-based competitive counterflow assay developed for organic anion transporting polypeptides 1A2, 1B1, 1B3 and 2B1 identifies pentamidine as a selective OATP1A2 substrate","volume":"37","author":"Ungv\u00e1ri","year":"2023","journal-title":"FASEB J"},{"key":"2025040317231902100_bib40","doi-asserted-by":"crossref","first-page":"e21863","DOI":"10.1096\/fj.202100648R","article-title":"8-acetoxy-trisulfopyrene as the first activatable fluorogenic probe for add-and-read assessment of Organic anion-transporting polypeptides, OATP1B1, OATP1B3, and OATP2B1","volume":"35","author":"Ungv\u00e1ri","year":"2021","journal-title":"FASEB J"},{"key":"2025040317231902100_bib41","doi-asserted-by":"crossref","first-page":"935.5","DOI":"10.1096\/fasebj.30.1_supplement.935.5","article-title":"Establishing the competitive counterflow assay for OATP1B1 and OATP1B3","volume":"30","author":"Katuwal","year":"2016","journal-title":"FASEB J"},{"key":"2025040317231902100_bib42","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-21-0023","article-title":"Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation","volume":"27","author":"Hayden","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025040317231902100_bib43","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/pharmaceutics12090856","article-title":"Role of OATP1B1 and OATP1B3 in drug-drug interactions mediated by tyrosine kinase inhibitors","volume":"12","author":"Garrison","year":"2020","journal-title":"Pharmaceutics"},{"key":"2025040317231902100_bib44","doi-asserted-by":"crossref","first-page":"9711179","DOI":"10.1155\/2021\/9711179","article-title":"OATP1B1 plays an important role in the transport and treatment efficacy of sorafenib in hepatocellular carcinoma","volume":"2021","author":"Wen","year":"2021","journal-title":"Dis Markers"},{"key":"2025040317231902100_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/cancers10120503","article-title":"Transporter and lysosomal mediated (Multi)drug resistance to tyrosine kinase inhibitors and potential strategies to overcome resistance","volume":"10","author":"de Klerk","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025040317231902100_bib46","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2119\/molmed.2014.00059","article-title":"Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function","volume":"20","author":"Ma","year":"2014","journal-title":"Mol Med"},{"key":"2025040317231902100_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/mol.111.076299","article-title":"Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo","volume":"82","author":"Zhao","year":"2012","journal-title":"Mol Pharmacol"},{"key":"2025040317231902100_bib48","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.4161\/cc.22382","article-title":"Erlotinib antagonizes ABC transporters in acute myeloid leukemia","volume":"11","author":"Lainey","year":"2012","journal-title":"Cell Cycle"},{"key":"2025040317231902100_bib49","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2015.136754","article-title":"Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo","volume":"101","author":"Ebert","year":"2016","journal-title":"Haematologica"},{"key":"2025040317231902100_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s12276-020-0453-6","article-title":"Correction: alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo","volume":"52","author":"Yang","year":"2020","journal-title":"Exp Mol Med"},{"key":"2025040317231902100_bib51","doi-asserted-by":"crossref","first-page":"640957","DOI":"10.3389\/fcell.2021.640957","article-title":"Cabozantinib reverses topotecan resistance in human non-small cell lung cancer NCI-H460\/TPT10 cell line and tumor xenograft model","volume":"9","author":"Lei","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025040317231902100_bib52","doi-asserted-by":"crossref","first-page":"115797","DOI":"10.1016\/j.taap.2021.115797","article-title":"Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy","volume":"434","author":"Sorf","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"2025040317231902100_bib53","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41422-023-00870-8","article-title":"Cryo-EM structures of human organic anion transporting polypeptide OATP1B1","volume":"33","author":"Shan","year":"2023","journal-title":"Cell Res"},{"key":"2025040317231902100_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/dmd.117.076554","article-title":"Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib","volume":"46","author":"Ellawatty","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"2025040317231902100_bib55","doi-asserted-by":"crossref","first-page":"e164646","DOI":"10.1172\/jci.insight.164646","article-title":"Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0332\/3491222\/crc-24-0332.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/9\/2489\/3499516\/crc-24-0332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/9\/2489\/3499516\/crc-24-0332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:06:58Z","timestamp":1743728818000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/9\/2489\/748576\/Systematic-Evaluation-of-Tyrosine-Kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0332","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7462071","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7462071.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.27087711","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087696","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087717","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087705","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727795","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087705.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727783","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727777","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727789","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087690","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087717.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087699.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087714","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087720","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087699","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087696.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087687","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087708","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087708.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087711.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727786","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087687.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727798","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727780","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087690.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727792","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087693.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087693","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087714.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27087720.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}